Clinical trials: Metastatic (Stage IV) Breast Cancer
Metastatic Breast Cancer
Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes
Study assessing efficacy of a Cisplatine- Métronomic cyclophosphamide treatment in Patients with Metastatic Triple Negative breast Cancer Secondary Resistant to Anthracyclines and Taxanes.
- Trial name
- META2 (NCT01910844)
- Testing
- Cisplatin, Cyclophosphamide
- Where
- France
- Volunteers
- 3 people
- Sponsor
- Centre Jean Perrin
Breast Cancer
Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer
The purposes of this study are : to investigate the safety and clinical efficacy of sole therapy with DLBS1425 in suppressing disease-(tumour) progression in subjects with advanced/metastatic breast cancer; and to determine the…
- Trial name
- NCT01006785
- Testing
- DLBS1425
- Where
- 3 sites in Indonesia
- Volunteers
- 15 people
- Sponsor
- Dexa Medica Group
Breast Cancer, Breast Cancer Stage IV
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
The purpose of this study to find out whether a very low carbohydrate diet (ketogenic diet), a low carbohydrate diet, or the study drug canagliflozin can prevent high blood sugar and may improve the effectiveness of cancer…
- Conditions
- Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer
- Trial name
- NCT05090358
- Testing
- Ketogenic Diet, Low Carbohydrate Diet, Alpelisib
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with QS21 may cause a stronger immune response and kill more tumor cells.
- Trial name
- NCT00470574
- Testing
- QS21, sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine, immunoenzyme technique
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hormone Receptor-positive Metastatic Breast Cancer, HER2-negative Metastatic Breast Cancer
Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management
The MINERVA Trial aims to evaluate safety, efficacy and quality of life (QoL) for the combination of Abemaciclib with an Aromatase Inhibitor or Fulvestrant in pre- and postmenopausal patients with metastatic hormone receptor…
- Trial name
- MINERVA (NCT05362760)
- Testing
- Abemaciclib + Aromatase Inhibitor, Abemaciclib + Fulvestrant
- Where
- 54 sites in Germany, Switzerland
- Volunteers
- 300 people
- Sponsor
- Prof. Wolfgang Janni